Core Insights - A total of 22 financing events were disclosed on June 20, 2025, involving 15 domestic companies and 7 foreign companies, with a total financing amount of approximately 14.189 billion RMB [2] - The enterprise service sector had the highest number of financing events, while the smart technology sector had the highest financing amount [2] - In the healthcare sector, there were 5 financing events involving 3 domestic companies and 2 foreign companies, totaling approximately 1.138 billion RMB [2] Domestic Healthcare Sector - Three domestic healthcare companies received funding, totaling approximately 1.074 billion RMB: - Zhejiang Taide Pharmaceutical completed a 10 million USD Pre-IPO financing, with investors including Weiguang Venture Capital and Shiyao Group [2] - United Imaging Intelligence completed a 1 billion RMB Series A financing, ranking first in all Series A financing this year [2] - Beijian Testing completed a 10 million RMB Series A financing, focusing on biosafety and animal laboratories [2] Foreign Healthcare Sector - Two foreign healthcare companies received funding, totaling approximately 64 million RMB: - SerImmune completed an 8 million USD Series A financing, ranking in the top 50 for Series A financing this year [3] - Droplet IV completed a 2 million USD seed round financing [3]

Group 1 - The company, TIDE Pharmaceutical (03880.HK), has launched an IPO, planning to issue 16.8 million shares globally, with 15.12 million shares for international offering and 1.68 million shares for public offering in Hong Kong [1] - The expected price range for each share is between HKD 28.40 and HKD 30.60, with estimated net proceeds from the global offering around HKD 411 million after deducting underwriting commissions and other expenses [1] - The funds raised will be used to expand service capacity and production in the US and China, increase capacity at the Qiantang Park, and build facilities in the Pharmaceutical Town [1] Group 2 - TIDE Pharmaceutical has entered cornerstone investment agreements with CSPC Pharmaceutical Group (01093.HK) and Welight Capital, with a total subscription amount of approximately USD 10 million [2] - In 2023, TIDE Pharmaceutical is the third largest global CRDMO focused on peptides, holding a market share of 1.5%, providing CRO and CDMO services primarily for API rather than finished drugs [2] - The company has established stable customer relationships in over 50 countries, with peptide drugs generally showing better tolerability, specificity, and bioactivity compared to chemical drugs [2] Group 3 - TIDE Pharmaceutical's revenue fluctuated from 2022 to 2024, with revenues of approximately RMB 351 million, RMB 337 million, and RMB 442 million, and net profits of approximately RMB 53.98 million, RMB 48.90 million, and RMB 59.17 million respectively [3] - In 2024, CDMO service revenue reached RMB 330 million, accounting for 74.6% of total revenue, with 55% of revenue coming from the US market, significantly higher than the 21.4% from the Chinese market [3] - The company indicated that recent US-China trade tensions may introduce uncertainties, but believes that new tariff policies will not have a direct or immediate significant impact on its business operations or financial performance [3]